BIONIK LABORATORIES CORP. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2023-06-27: Form 8-K; Period of report 2023-06-22; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2023-06-16: Form 8-K; Period of report 2023-06-13; Description 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events; Details 1.01.
- 2023-06-16: Form 8-K; Period of report 2023-06-09; Description 3.02 Unregistered Sales of Equity Securities; Details 3.02.
- 2023-06-15: Form 8-K; Period of report 2023-06-15; Description 7.01 Regulation FD Disclosure; Details 7.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2023-06-27 | 8-K | 2023-06-22 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 As previously announced by Bionik Laboratories Corp. (the “Company”), and in relation to its commencement of certain cost-cutting measures to maximize available resources, the Company considered decreasing the size of its Board of Directors (the “Board”), with voluntary resignations of one or more directors. | tm2319781-1_8k.htm |
| 2023-06-16 | 8-K | 2023-06-13 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 1.01 The information set forth in Item 2.03 is incorporated by reference into this Item 1.01. 2.03 On June 13, 2023, Bionik Laboratories Corp. (the “Company”) launched a new private offering (the “Private Offering”) of its convertible promissory notes (the “Notes”) of up to $2,000,000, with an initial subscription of $220,000 from an affiliate of the Company’s Chairman, Andre-Jacques Auberton-Herve (the “Holder”). 3.02 The disclosure set forth above in Item 2.03 of this Current Report on Form 8-K relating to the issuance of the Note is incorporated by reference herein. 8.01 The Company’s Board of Directors and management have commenced, and are continuing to explore, certain cost-cutting measures to maximize available resources while it seeks to raise capital through the Private Offering and increase revenues. | tm2318913d1_8k.htm |
| 2023-06-16 | 8-K | 2023-06-09 | 3.02 Unregistered Sales of Equity Securities | 3.02 On June 9, 2023, Bionik Laboratories Corp. (the “Company”) directed the issuance, as of May 31, 2023, of an aggregate of 1,518,725 shares of the Company’s common stock, as payment in full for all accrued and unpaid directors fees and consulting fees, as the case may be, to each of Remi Gaston-Dreyfus, Andre-Jacques Auberton-Herve, Charles Matine and Michal Prywata, through May 31, 2023. | tm2318913d2_8k.htm |
| 2023-06-15 | 8-K | 2023-06-15 | 7.01 Regulation FD Disclosure | 7.01 On June 15, 2023, Bionik Laboratories Corp. (the “Company”) issued a press release to announce that it continues to grow its partnership with Lifepoint Health, with four new installations of the InMotion® ARM robotic device in Phoenix, Arizona, Sacramento, California, Brownsburg, Indiana, and Louisville, Kentucky. | tm2318822d1_8k.htm |
| 2023-05-23 | 8-K | 2023-05-23 | 7.01 Regulation FD Disclosure | 7.01 On May 23, 2023, Bionik Laboratories Corp. (the “Company”) issued a press release to announce that it has experienced a significant increase in patient volume at its rehabilitation center, Tower Physical Therapy & Rehab, in Clermont, Florida. | tm2316553d1_8k.htm |
| 2023-05-04 | 8-K | 2023-05-04 | 7.01 Regulation FD Disclosure | 7.01 On May 4, 2023, Bionik Laboratories Corp. (the “Company”) issued a press release to announce that it has entered into a distribution agreement with Pro-Med Technology LTD, a provider of medical equipment based in Hong Kong. | tm2314547d1_8k.htm |
| 2023-04-26 | 8-K | 2023-04-20 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 The information set forth in Item 2.03 is incorporated by reference into this Item 1.01. 2.03 On April 20, 2023, Bionik Laboratories Corp. (the “Company”) issued a convertible promissory note (the “Note”) and borrowed $250,000 (the “Loan”) from an existing stockholder of the Company (the “Holder”). 3.02 The disclosure set forth above in Item 2.03 of this Current Report on Form 8-K relating to the issuance of the Note is incorporated by reference herein. | tm2313829d1_8k.htm |
| 2023-02-23 | 8-K | 2023-02-16 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 The information set forth in Item 2.03 is incorporated by reference into this Item 1.01. 2.03 On February 16, 2023, Bionik Laboratories Corp. (the “Company”) issued a convertible promissory note (the “Note”) and borrowed $500,000 (the “Loan”) from an affiliate of Remi Gaston-Dreyfus, a director of the Company (the “Holder”). 3.02 The disclosure set forth above in Item 2.03 of this Current Report on Form 8-K relating to the issuance of the Note is incorporated by reference herein. | tm237594d1_8k.htm |
| 2023-02-08 | 8-K | 2023-02-08 | 2.02 Results of Operations and Financial Condition | 2.02 On February 8, 2023, Bionik Laboratories Corp. issued a press release announcing its financial results and corporate highlights for the fiscal quarter ended December 31, 2022. | tm235066d1_8k.htm |
| 2023-01-20 | 8-K | 2023-01-19 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The Annual Meeting of Stockholders (the “Annual Meeting”) of Bionik Laboratories Corp. (the “Company”) was held on January 19, 2023. | tm234067d1_8k.htm |